Business Context and Reporting Period
Company: SeaStar Medical Holding Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: June 6, 2023
Reporting Period: Event date June 6, 2023; Signed June 9, 2023
Business Context: The Company is an emerging growth company incorporated in Delaware, with principal executive offices in Denver, Colorado. Its common stock and warrants trade on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a specific corporate transaction.
Material Changes and Transaction Details
The Company entered into a Material Definitive Agreement with Vellar Opportunity Fund SPV LLC – Series 4 ("Vellar") on June 6, 2023. Key terms include:
- Share Issuance: The Company agreed to issue and deliver 1,000,000 shares of common stock (par value $0.0001) to Vellar.
- Settlement Purpose: These "Settlement Shares" were issued in lieu of the Company's obligation to pay certain maturity consideration under a Prepaid Forward Purchase Agreement (FPA) dated October 17, 2022.
- Trigger Event: The issuance was triggered by the occurrence of a VWAP Trigger Event as defined in the FPA.
- Termination: Upon execution of the Agreement, all obligations of both parties under the original FPA were terminated.
- Registration: The Company is required to register the Settlement Shares on a registration statement filed pursuant to the Securities Act of 1933.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management outlook, or specific risk factors beyond the disclosure of the transaction itself. The text notes that the disclosure is a summary and is qualified in its entirety by the full Share Issuance and Settlement Agreement, which is to be filed as an exhibit to the Quarterly Report for the period ending June 30, 2023.
Investor Verification Checklist
- Verify the impact of the 1,000,000 share issuance on total outstanding shares and potential dilution.
- Review the full Share Issuance and Settlement Agreement (exhibit to the upcoming Q2 2023 10-Q) for detailed terms regarding the VWAP Trigger Event.
- Confirm the status of the registration statement required for the Settlement Shares.
- Assess the historical context of the October 17, 2022 Prepaid Forward Purchase Agreement to understand the original capital raised and obligations settled.